Citations

Mayo Clinic

Showing 10 of 108599 citations.

Endoscopic Resection of Sinonasal Mucosal Melanoma has Comparable Outcomes to Open Approaches
Miglani, Amar , Patel, Samir H. , Hinni, Michael L., Hayden, Richard E. , Kosiorek, Heidi , Lal, Devyani

American Journal of Rhinology & Allergy | May 11, 2017 | Volume: 31 | Issue: 3 | Pages: 200-204

10.2500/ajra.2017.31.4435 | PMID 28490408 Get It

Background Endoscopic endonasal resection (EER) of sinonasal mucosal melanoma (SMM) is a newer surgical alternative to traditional external and/or open resection (OR). Studies on long-term outcomes are necessary to validate EER for this aggressive sinonasal malignancy. Objective To compare outcomes of EER versus OR in SMM. Methods A case series of patients who underwent surgical resection of SMM at a tertiary-care institution (2000–2015) was studied retrospectively. Demographics, tumor site and stage, surgical approach, surgical margin status, local control, and survival were compared between those who underwent EER and OR. Results Twenty-two patients met inclusion criteria. Nine underwent EER and 13 underwent OR. The mean age in the EER and OR groups was similar, 78.7 and 72.3 years, respectively. Two-thirds of patients were women (EER, 66.7%; OR, 61.5%). The nasal cavity was the most common primary tumor site (EER, 77.8%; OR, 84.6%). The local tumor stage in both groups was similar, with the majority of cases being T4 (EER, 55.6%; OR, 61.5%; p = 0.99). Negative margins were achieved in all EERs and in 69.2% of ORs. Median follow-up was 25.0 months for the overall group (range, 1.7–172.9 months), 32.6 months (range, 3.4–58.7 months) for EER and 14.1 months (range, 1.7–172.9 months) for OR cohorts. The 5-year overall survival was statistically similar in both groups (EER, 53.3%; OR, 22.7%; p = 0.214) as was disease-free survival (EER, 55.6%; OR, 22.8%; p = 0.178). Local control, however, was significantly higher in the EER cohort (EER, 85.7%; OR, 37.6%; p = 0.026). Conclusion In carefully selected patients with sinonasal melanoma, endoscopic surgery with an experienced team may offer comparable survival and improved local control over open surgery. Prospective, multicentered studies with larger cohorts are needed to validate these results.
Attitudes, Beliefs, Practices, and Concerns Among Clinicians Prescribing Opioids in a Large Academic Institution
Ebbert, Jon O. , Philpot, Lindsey M. , Clements, Casey M. , Lovely, Jenna K. , Nicholson, Wayne T. , Jenkins, Sarah M. , Lamer, Tim J. , Gazelka, Halena M. , Philpot, Lindsey M

Pain Medicine | May 10, 2017 | Volume: 19 | Issue: 9 | Pages: 1790-1798

10.1093/pm/pnx140 | PMID 29177439 Get It

Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population
Levine, Michael , Stellpflug, Sam, Pizon, Anthony F. , Traub, Stephen J., Vohra, Rais, Wiegand, Timothy J. , Traub, Nicole A., Tashman, David, Desai, Shoma , Chang, Jamie , Nathwani, D, Thomas, Stephen, Stellpflug, Samuel J. , Thomas, Stephen H. , Traub, Stephen, Traub, Nicole, Thomas, Stephen H

Clinical Toxicology | May 10, 2017 | Volume: 55 | Issue: 6 | Pages: 569-572

10.1080/15563650.2017.1291945 | PMID 28489461 Get It

Comparative Toxicity of Purified Human Eosinophil Granule Cationic Proteins for Schistosomula of Schistosoma Mansoni *
Ackerman, Steven J. , Gleich, Gerald J. , Butterworth, A , Loegering, David A., Richardson, Brian A.

The American Journal of Tropical Medicine and Hygiene | May 10, 2017 | Volume: 34 | Issue: 4 | Pages: 735-745

10.4269/ajtmh.1985.34.735 | PMID 4025686 Get It

Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease
Sorajja, Paul , Borlaug, Barry A. , Dimas, V. Vivian , Forfia, Paul R. , Givertz, Michael M., Kapur, Navin K. , Naidu, Srihari S. , Sorajja, Paul , Fang, James C. , Givertz, Michael M. , Kern, Morton J. , Borlaug, Barry A

Catheterization and Cardiovascular Interventions | May 10, 2017 | Volume: 89 | Issue: 7 | Pages: 1294-1299

10.1002/ccd.27036 | PMID 28489324 Get It

SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease
Sorajja, Paul , Borlaug, Barry A. , Dimas, Vasiliki V., Fang, James C., Forfia, Paul R. , Givertz, Michael M. , Kapur, Navin K. , Naidu, Srihari S. , Dimas, V. Vivian , Sorajja, Paul , Dimas, Vasiliki V., Kern, Morton J. , Borlaug, Barry A

Catheterization and Cardiovascular Interventions | May 10, 2017 | Volume: 89 | Issue: 7 | Pages: No page available

10.1002/ccd.26888 | PMID 28489331 Get It

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma
McWilliams, Robert R. , Foster, Nathan R. , Mahoney, Michelle R., Smyrk, Thomas C. , Ames, Matthew M. , Horvath, Laura E., Hobday, Timothy J. , Jatoi, Aminah , Meyers, Jeffrey P., Jatoi, Aminah , Murray, Joseph A. , Schneider, Daniel , Goetz, Matthew P. , McWilliams, Robert R

Cancer | May 10, 2017 | Volume: 123 | Issue: 18 | Pages: 3494-3501

10.1002/cncr.30766 | PMID 28493308 Get It

BACKGROUNDOxaliplatin in combination with either 5‐fluorouracil or capecitabine is commonly used as first‐line therapy for patients with small bowel adenocarcinoma. The addition of irinotecan improves survival in other gastrointestinal tumors but at the cost of hematologic toxicity. The authors performed a phase 2 cooperative group study (North Central Cancer Treatment Group N0543, Alliance) using genotype‐dosed capecitabine, irinotecan, and oxaliplatin (gCAPIRINOX), with dosing assigned based on UDP glucuronosyltransferase family 1 member A1 (UGT1A1) genotype to test: 1) whether the addition of irinotecan would improve outcomes; and 2) whether UGT1A1 genotype‐based dosing could optimize tolerability.METHODSPreviously untreated patients with advanced small bowel adenocarcinoma received irinotecan (day 1), oxaliplatin (day 1), and capecitabine (days 2‐15) in a 21‐day cycle and were dosed with gCAPIRINOX according to UGT1A1*28 genotypes (6/6, 6/7, and 7/7).RESULTSA total of 33 patients (17 with the 6/6 genotype, 10 with the 6/7 genotype, and 6 with the 7/7 genotype) were enrolled from October 2007 to November 2013; 73% were male, with a mean age of 64 years (range, 41‐77 years). Location of the primary tumor included the duodenum (58%), jejunum (30%), and ileum (9%). The regimen yielded a confirmed response rate of 37.5% (95% confidence interval, 21%‐56%), with a median progression‐free survival of 8.9 months and a median overall survival of 13.4 months. Neither hematologic toxicity (grade ≥3 in 52.9%, 30.0%, and 33.3%, respectively, of the 6/6, 6/7, and 7/7 genotype groups) nor tumor response rate (41.2%, 33%, and 33%, respectively) were found to differ significantly by UGT1A1 genotype.CONCLUSIONSUGT1A1 genotype‐directed dosing (gCAPIRINOX) appears to be feasible with favorable rates of hematologic toxicity compared with prior 3‐drug studies in unselected patients. Larger studies would be needed to determine the regimen's comparability to oxaliplatin and capecitabine (CapeOx) alone or if response/toxicity differs among patients with different UGT1A1 genotypes. Cancer 2017;123:3494‐501. © 2017 American Cancer Society.
Methadone-Induced Neurotoxicity in Advanced Cancer: A Case Report
Hoff, A.M., Hartwig, Kristopher N., Hoff, Ann M, Rosielle, Drew A.

Journal of Palliative Medicine | May 10, 2017 | Volume: 20 | Issue: 9 | Pages: 1042-1044

10.1089/jpm.2016.0502 | PMID 28488910 Get It

Abstract Methadone use as a second-line agent for severe cancer-related pain is increasing in the field of hospice and palliative care. It has a number of qualities that make its use favorable, including lack of known active metabolites and presumed relative safety from adverse effects such as opioid-induced neurotoxicity (OIN). This article describes a case of a patient undergoing treatment of severe cancer-related pain who developed OIN in the setting of oral methadone use. As the use of methadone increases, more research into its pharmacologic and pharmacokinetic properties will be necessary.
Editorial Comment on “Distinguishing Failure to Cure From Complication After Penile Prosthesis Implantation”
Trost, Landon

The Journal of Sexual Medicine | May 10, 2017 | Volume: 14 | Issue: 5 | Pages: 738-739

10.1016/j.jsxm.2017.02.017 | PMID 28499522 Get It

Immune modulator therapy for microscopic colitis in a case series of 73 patients
Cotter, Thomas G. , Kamboj, Amrit K. , Hicks, Stephen B., Tremaine, William J., Loftus, Edward V. , Pardi, Darrell S. , Cotter, T G , Loftus, Edward V

Alimentary Pharmacology & Therapeutics | May 10, 2017 | Volume: 46 | Issue: 2 | Pages: 169-174

10.1111/apt.14133 | PMID 28488312 Get It

SummaryBackgroundMicroscopic colitis (MC) is a common cause of chronic diarrhoea. Various treatment options have been described, but there are limited data describing outcomes of corticosteroid‐sparing treatments.AimTo evaluate the outcomes of patients with active MC treated with immune modulators.MethodsAll patients seen at Mayo Clinic, Rochester between January 1, 1997 and November 30, 2016 with a histological diagnosis of MC were identified. Patients treated with an immune modulator of interest were selected and clinical outcomes recorded.ResultsSeventy‐three MC patients (50 collagenous colitis and 23 lymphocytic colitis) with a median disease duration of 24 months (range, 7‐60) were included. The indications for treatment were budesonide‐refractoriness in 66%, budesonide dependence in 29%, and budesonide intolerance in 5%. Median age was 51.8 years (range, 43.4‐63.1) and 61 (84%) were female. Thiopurines were used in 49 patients (67%) for a median of 4 months (range, 1.5‐15). Complete and partial response occurred in 43% and 22% respectively. Adverse effects resulting in therapy cessation occurred in 17 patients (35%). Twelve patients (16%) were treated with methotrexate for a median of 14 months (3‐18.8). Complete and partial response occurred in 58% and 17%, respectively. Anti‐TNF therapy was used in 10 patients (14%) for a median of 4 months (range, 2.3‐5.5). Complete response occurred in four patients and partial response in four patients.ConclusionsThe majority of patients with active MC responded to thiopurines, methotrexate, or anti‐TNF therapy. Larger controlled studies are required to confirm the efficacy and safety of these medications in MC.